These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35428179)

  • 21. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
    Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
    J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein(a) for risk assessment in patients with established coronary artery disease.
    O'Donoghue ML; Morrow DA; Tsimikas S; Sloan S; Ren AF; Hoffman EB; Desai NR; Solomon SD; Domanski M; Arai K; Chiuve SE; Cannon CP; Sacks FM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(6):520-7. PubMed ID: 24161323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Rikhi R; Hammoud A; Ashburn N; Snavely AC; Michos ED; Chevli P; Tsai MY; Herrington D; Shapiro MD
    Atherosclerosis; 2022 Dec; 363():102-108. PubMed ID: 36253168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
    Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
    Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
    Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
    Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol.
    Liu Y; Zeng Z; Yu X; Li T; Yao Y; Chen R; Zheng J
    Rev Cardiovasc Med; 2020 Mar; 21(1):147-153. PubMed ID: 32259914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study.
    Afshar M; Rong J; Zhan Y; Chen HY; Engert JC; Sniderman AD; Larson MG; Vasan RS; Thanassoulis G
    J Am Heart Assoc; 2020 Sep; 9(18):e014711. PubMed ID: 32892691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.
    Verbeek R; Hoogeveen RM; Langsted A; Stiekema LCA; Verweij SL; Hovingh GK; Wareham NJ; Khaw KT; Boekholdt SM; Nordestgaard BG; Stroes ESG
    Eur Heart J; 2018 Jul; 39(27):2589-2596. PubMed ID: 29931232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
    Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
    Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Zhang J; He L
    BMC Cardiovasc Disord; 2021 Apr; 21(1):169. PubMed ID: 33845772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.
    Jubran A; Zetser A; Zafrir B
    Cardiol J; 2019; 26(5):511-518. PubMed ID: 30234895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study.
    Dai W; Zhang Z; Zhao S
    Lipids Health Dis; 2018 Dec; 17(1):273. PubMed ID: 30509306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome.
    Liu HH; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Dong Q; Qian J; Dou KF; Li JJ
    J Transl Med; 2022 May; 20(1):243. PubMed ID: 35619146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL.
    Wang JJ; Han AZ; Meng Y; Gong JB; Zhang CN; Li K; Liu YX
    Clin Biochem; 2010 Apr; 43(6):571-5. PubMed ID: 20060390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion.
    Shen Y; Chen S; Dai Y; Wang XQ; Zhang RY; Yang ZK; Hu J; Lu L; Ding FH; Shen WF
    Cardiovasc Diabetol; 2019 Jun; 18(1):82. PubMed ID: 31234867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.